<!DOCTYPE html>
<html lang="zh-CN">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=5.0">
    <title>ç§‘ç ”æ—¥æŠ¥ - 2025-11-27</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", Arial, "Noto Sans", sans-serif, "Apple Color Emoji", "Segoe UI Emoji";
            line-height: 1.8;
            color: #2c3e50;
            background: linear-gradient(135deg, #f5f7fa 0%, #c3cfe2 100%);
            padding: 15px;
            font-size: 16px;
        }

        .container {
            max-width: 900px;
            margin: 0 auto;
            background: white;
            padding: 35px;
            border-radius: 16px;
            box-shadow: 0 10px 40px rgba(0,0,0,0.1);
        }

        /* æ ‡é¢˜ä¼˜åŒ– */
        h1 {
            color: #1a202c;
            font-size: 2em;
            border-bottom: 4px solid #667eea;
            padding-bottom: 15px;
            margin-bottom: 25px;
            font-weight: 700;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            -webkit-background-clip: text;
            -webkit-text-fill-color: transparent;
            background-clip: text;
        }

        h2 {
            color: #2d3748;
            font-size: 1.5em;
            margin-top: 40px;
            margin-bottom: 20px;
            padding-left: 15px;
            border-left: 5px solid #667eea;
            font-weight: 600;
        }

        h3 {
            color: #4a5568;
            font-size: 1.25em;
            margin-top: 28px;
            margin-bottom: 14px;
            font-weight: 600;
        }

        /* åˆ†ç±»æµè§ˆæŠ˜å åŠŸèƒ½ */
        details {
            margin: 20px 0;
            border-radius: 8px;
            overflow: hidden;
        }

        details summary {
            cursor: pointer;
            padding: 15px 20px;
            background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%);
            color: #2d3748;
            font-size: 1.25em;
            font-weight: 600;
            text-align: right;
            direction: rtl;
            border-right: 5px solid #667eea;
            transition: all 0.3s ease;
            list-style: none;
            user-select: none;
        }

        details summary * {
            direction: ltr;
        }

        details summary::-webkit-details-marker {
            display: none;
        }

        details summary::before {
            content: 'â–¶';
            display: inline-block;
            margin-left: 10px;
            transition: transform 0.3s ease;
            font-size: 0.8em;
        }

        details[open] summary::before {
            transform: rotate(90deg);
        }

        details summary:hover {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            box-shadow: 0 4px 12px rgba(102, 126, 234, 0.3);
        }

        details[open] summary {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            border-right-color: white;
        }

        details .details-content {
            padding: 20px;
            background: white;
            border: 1px solid #e9ecef;
            border-top: none;
        }

        h4 {
            color: #718096;
            font-size: 1.1em;
            margin-top: 22px;
            margin-bottom: 12px;
            font-weight: 600;
        }

        p {
            margin-bottom: 16px;
            line-height: 1.8;
        }

        blockquote {
            background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%);
            border-left: 4px solid #667eea;
            padding: 18px 22px;
            margin: 22px 0;
            border-radius: 8px;
            color: #4a5568;
            font-size: 0.95em;
            box-shadow: 0 2px 8px rgba(0,0,0,0.05);
        }

        blockquote p {
            margin-bottom: 8px;
        }

        blockquote p:last-child {
            margin-bottom: 0;
        }

        blockquote em {
            font-style: normal;
            color: #718096;
            font-size: 0.9em;
        }

        blockquote a {
            color: #667eea;
            font-weight: 500;
            border-bottom: 1px solid rgba(102, 126, 234, 0.3);
        }

        blockquote a:hover {
            color: #764ba2;
            border-bottom-color: #764ba2;
        }

        /* é¡¶éƒ¨ç½²åï¼ˆå±…å³ï¼‰ */
        .powered-by-top {
            text-align: right;
            font-size: 0.85em;
            color: #718096;
            font-style: italic;
            margin: 12px 0;
            padding-right: 5px;
        }

        .powered-by-top a {
            color: #667eea;
            font-weight: 500;
            border-bottom: 1px solid rgba(102, 126, 234, 0.3);
        }

        .powered-by-top a:hover {
            color: #764ba2;
            border-bottom-color: #764ba2;
        }

        /* AI æ€»ç»“åŒºåŸŸä¼˜åŒ– */
        .ai-summary {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            padding: 28px;
            border-radius: 16px;
            margin: 30px 0;
            box-shadow: 0 12px 35px rgba(102, 126, 234, 0.35);
            position: relative;
            overflow: hidden;
        }

        .ai-summary::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -50%;
            width: 200%;
            height: 200%;
            background: radial-gradient(circle, rgba(255,255,255,0.1) 0%, transparent 70%);
            pointer-events: none;
        }

        .ai-summary h2 {
            color: white;
            border-left: none;
            border-right: none;
            margin-top: 0;
            margin-bottom: 18px;
            padding-left: 15px;
            padding-right: 0;
            text-align: left;
            direction: ltr;
        }

        .ai-summary h3 {
            color: #f0f0f0;
            margin-top: 18px;
            border-right: 3px solid rgba(255,255,255,0.5);
            padding-right: 12px;
            padding-left: 0;
            text-align: right;
            direction: rtl;
        }

        .ai-summary h3 * {
            direction: ltr;
        }

        .ai-summary blockquote {
            background: rgba(255,255,255,0.15);
            border-left-color: white;
            color: white;
            backdrop-filter: blur(10px);
        }

        .ai-summary p {
            color: white;
        }

        .ai-summary strong {
            color: #fff;
            font-weight: 600;
        }

        ul, ol {
            margin-left: 28px;
            margin-bottom: 18px;
        }

        li {
            margin-bottom: 12px;
            line-height: 1.8;
        }

        /* é“¾æ¥ä¼˜åŒ– */
        a {
            color: #667eea;
            text-decoration: none;
            border-bottom: 1px solid transparent;
            transition: all 0.3s ease;
            font-weight: 500;
        }

        a:hover {
            border-bottom-color: #667eea;
            color: #764ba2;
        }

        /* è¡¨æ ¼ä¼˜åŒ– */
        table {
            width: 100%;
            border-collapse: collapse;
            margin: 20px 0;
            box-shadow: 0 2px 12px rgba(0,0,0,0.08);
            border-radius: 10px;
            overflow: hidden;
        }

        th, td {
            border: 1px solid #e2e8f0;
            padding: 14px 18px;
            text-align: left;
        }

        th {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            font-weight: 600;
            font-size: 0.95em;
        }

        tr:nth-child(even) {
            background: #f8f9fa;
        }

        tr:hover {
            background: #e9ecef;
            transition: background 0.3s ease;
        }

        /* å…³é”®è¯ç»Ÿè®¡è¡¨æ ¼ç‰¹æ®Šæ ·å¼ï¼ˆæ›´ç´§å‡‘ï¼‰ */
        .keywords-table {
            font-size: 0.9em;
            max-width: 600px;
        }

        .keywords-table th,
        .keywords-table td {
            padding: 10px 14px;
        }

        .keywords-table th {
            font-size: 0.9em;
        }

        hr {
            border: none;
            border-top: 2px solid #e2e8f0;
            margin: 40px 0;
        }

        strong {
            color: #2d3748;
            font-weight: 600;
        }

        code {
            background: #f1f5f9;
            padding: 3px 8px;
            border-radius: 5px;
            font-family: "SF Mono", Monaco, Consolas, "Courier New", monospace;
            font-size: 0.9em;
            color: #e53e3e;
        }

        /* ç¾åŒ–æ»šåŠ¨æ¡ */
        ::-webkit-scrollbar {
            width: 8px;
            height: 8px;
        }

        ::-webkit-scrollbar-track {
            background: #f1f1f1;
            border-radius: 4px;
        }

        ::-webkit-scrollbar-thumb {
            background: #667eea;
            border-radius: 4px;
        }

        ::-webkit-scrollbar-thumb:hover {
            background: #764ba2;
        }

        /* ç§»åŠ¨ç«¯ä¼˜åŒ– */
        @media (max-width: 768px) {
            body {
                padding: 8px;
                font-size: 15px;
            }

            .container {
                padding: 22px 18px;
                border-radius: 12px;
            }

            h1 {
                font-size: 1.6em;
                padding-bottom: 12px;
                margin-bottom: 20px;
            }

            h2 {
                font-size: 1.3em;
                margin-top: 30px;
                padding-left: 12px;
            }

            h3 {
                font-size: 1.15em;
            }

            h4 {
                font-size: 1.05em;
            }

            blockquote {
                padding: 14px 16px;
                margin: 18px 0;
            }

            .ai-summary {
                padding: 20px;
                margin: 22px 0;
            }

            .ai-summary-header {
                flex-direction: column;
                align-items: flex-start;
            }

            .powered-by {
                margin-left: 0;
                margin-top: 8px;
            }

            table {
                font-size: 0.85em;
            }

            th, td {
                padding: 10px 12px;
            }

            .keywords-table {
                font-size: 0.8em;
            }

            .keywords-table th,
            .keywords-table td {
                padding: 8px 10px;
            }

            ul, ol {
                margin-left: 22px;
            }
        }

        /* è¶…å°å±å¹• */
        @media (max-width: 480px) {
            body {
                font-size: 14px;
                padding: 5px;
            }

            .container {
                padding: 18px 14px;
            }

            h1 {
                font-size: 1.4em;
            }

            h2 {
                font-size: 1.2em;
            }

            .ai-summary {
                padding: 16px;
            }

            .powered-by {
                font-size: 0.7em;
            }
        }

        /* å¹³æ»‘æ»šåŠ¨ */
        html {
            scroll-behavior: smooth;
        }

        /* æé«˜å¯ç‚¹å‡»åŒºåŸŸ */
        @media (pointer: coarse) {
            a {
                padding: 4px 0;
                display: inline-block;
            }
        }

        /* æ‰“å°ä¼˜åŒ– */
        @media print {
            body {
                background: white;
                padding: 0;
            }

            .container {
                box-shadow: none;
                max-width: 100%;
            }

            .ai-summary {
                background: #f5f5f5;
                color: black;
                box-shadow: none;
            }

            .ai-summary h2,
            .ai-summary h3,
            .ai-summary p,
            .ai-summary strong {
                color: black;
            }
        }
    </style>
</head>
<body>
    <div class="container">
        <h1>ğŸ“… Daily Report - 2025-11-27</h1>
<blockquote>
<p>ä»Šæ—¥ç­›é€‰å‡º <strong>84</strong> æ¡å†…å®¹ï¼Œæ¥è‡ª <strong>4</strong> ä¸ªæ¥æº</p>
</blockquote>
<div class="powered-by-top">Powered by <a href="https://kyplus.de" target="_blank" rel="noopener noreferrer">ç§‘ç ”æ™®æ‹‰æ–¯</a> & <a href="https://claude.ai" target="_blank" rel="noopener noreferrer">Claude</a></div>

<hr />
<div class="ai-summary">
                <h2>ğŸ¤– ä»Šæ—¥AIæ™ºèƒ½æ€»ç»“</h2>
                <h3>ğŸ“° å…¬ä¼—å·</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
é¦–æ¬¡è¯å®è‚ ç™Œå¯åˆ©ç”¨ä¸Šçš®ç»†èƒå¯å¡‘æ€§å¯¹MAPKé€šè·¯æŠ‘åˆ¶å‰‚è€è¯ï¼›å“ˆä½›å›¢é˜Ÿæ„å»º170ä¸‡Tç»†èƒå›¾è°±ï¼Œä¸ºç”Ÿä¿¡æ³¨é‡Šæä¾›â€œé»„é‡‘æ ‡å°ºâ€ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
- å¾®ç”Ÿç‰©ç»„ä¸å…ç–«äº’ä½œæœºåˆ¶æ¢ç´¢ï¼Œåˆ©ç”¨å•ç»†èƒä¸ç©ºé—´å¤šç»„å­¦ã€‚<br />
- è‚¿ç˜¤å¾®ç¯å¢ƒä¸å…ç–«æ²»ç–—ç–—æ•ˆæå‡ï¼Œèšç„¦ä¸­æ€§ç²’ç»†èƒäºšå‹ã€ä¸‰çº§æ·‹å·´ç»“æ„ï¼ˆTLSï¼‰åˆ†æã€‚<br />
- è‚¿ç˜¤è€è¯æœºåˆ¶è§£æï¼Œæ¶‰åŠCAF-ç™Œç»†èƒé€šè®¯ã€åŸºå› ç»„å€å¢ã€å·¨å™¬ç»†èƒçº¿ç²’ä½“åŠŸèƒ½é‡å¡‘ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
- å¤šç»„å­¦ï¼ˆå•ç»†èƒã€ç©ºè½¬ã€ä»£è°¢ç»„ã€ChIP-seqç­‰ï¼‰è”åˆåˆ†æï¼Œæå‡ç ”ç©¶æ·±åº¦ä¸å‘æ–‡æ½œåŠ›ã€‚<br />
- æ–°å‹è‚¿ç˜¤èŠ¯ç‰‡æŠ€æœ¯æ¨¡æ‹Ÿå®ä½“ç˜¤å¾®ç¯å¢ƒï¼ŒåŠ©åŠ›CAR-Tç–—æ³•ç ”å‘ã€‚</p>
<h3>ğŸ§¬ æ•°æ®å‰æ²¿</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
EZH2ä¸TEADè”åˆé¶å‘æ²»ç–—Hippoé€šè·¯çªå˜ç™Œç—‡ï¼Œé€šè¿‡è‚¿ç˜¤å†…åœ¨çš„å…ˆå¤©å…ç–«ä¿¡å·è¯±å¯¼ç»†èƒå‡‹äº¡ï¼›åŒæ—¶ï¼ŒPRC2ä¸DNAç”²åŸºåŒ–ç›¸äº’ä½œç”¨ä»‹å¯¼ç¥ç»å†…åˆ†æ³Œå‰åˆ—è…ºç™Œè°±ç³»å¯å¡‘æ€§ï¼Œä¸ºç™Œç—‡æ²»ç–—æä¾›æ–°ç­–ç•¥ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
*   <strong>ç™Œç—‡è¡¨è§‚é—ä¼ è°ƒæ§ä¸æ²»ç–—</strong>ï¼šèšç„¦EZH2ã€DNMTã€PRC2ç­‰è¡¨è§‚é—ä¼ è°ƒæ§å› å­åœ¨å‰åˆ—è…ºç™Œã€ä¹³è…ºç™Œç­‰ç™Œç—‡å‘ç”Ÿå‘å±•ä¸­çš„ä½œç”¨ï¼Œæ¢ç´¢è”åˆé¶å‘æ²»ç–—ç­–ç•¥ã€‚<br />
*   <strong>è‚¿ç˜¤å…ç–«ä¸ä¿¡å·é€šè·¯</strong>ï¼šç ”ç©¶Hippoé€šè·¯çªå˜ç™Œç—‡çš„å†…åœ¨å…ç–«ä¿¡å·ï¼Œä»¥åŠCAR-NKç»†èƒç–—æ³•å¯¹è‚¿ç˜¤å…ç–«çš„é‡å¡‘ä½œç”¨ã€‚<br />
*   <strong>ç»†èƒè°±ç³»å¯å¡‘æ€§æœºåˆ¶</strong>ï¼šè§£æDNAç”²åŸºåŒ–ä¸PRC2åœ¨ç¥ç»å†…åˆ†æ³Œå‰åˆ—è…ºç™Œè°±ç³»å¯å¡‘æ€§ä¸­çš„è°ƒæ§æœºåˆ¶ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
*   <strong>å¤šç»„å­¦æ•´åˆåˆ†æ</strong>ï¼šç»“åˆRNA-seqã€ChIP-seqã€ATAC-seqã€RRBSç­‰æŠ€æœ¯ï¼Œæ·±å…¥è§£æåŸºå› è¡¨è¾¾ã€æŸ“è‰²è´¨å¯åŠæ€§ã€DNAç”²åŸºåŒ–åŠè›‹ç™½è´¨ç»“åˆæ¨¡å¼ã€‚<br />
*   <strong>å•ç»†èƒç©ºé—´è½¬å½•ç»„å­¦</strong>ï¼šæ­ç¤ºåµå·¢è‚¿ç˜¤æµ¸æ¶¦æ€§NKç»†èƒçš„è°ƒæ§ç½‘ç»œï¼Œä»¥åŠèƒç›˜ç»„ç»‡åœ¨å…ˆå…†å­ç—«ä¸­çš„ç©ºé—´è½¬å½•ç»„å­¦ç‰¹å¾ã€‚</p>
<h3>ğŸ”¬ æœŸåˆŠæ–‡ç« </h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
Camrelizumabè”åˆrivoceranibä½œä¸ºä¸å¯åˆ‡é™¤è‚ç»†èƒç™Œçš„ä¸€çº¿æ²»ç–—ï¼Œåœ¨å›½é™…ä¸‰æœŸä¸´åºŠç ”ç©¶ï¼ˆCARES-310ï¼‰ä¸­æ˜¾ç¤ºå‡ºä¼˜äºsorafenibçš„æœ€ç»ˆç–—æ•ˆã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
- è‚ç»†èƒç™Œä¸€çº¿æ²»ç–—ï¼šè¯„ä¼°Camrelizumabè”åˆrivoceranibä¸sorafenibçš„ç–—æ•ˆåŠå®‰å…¨æ€§ã€‚<br />
- IDHçªå˜èƒ¶è´¨ç˜¤ï¼šæ¢è®¨å¢åŠ ç¥ç»å¤–ç§‘åˆ‡é™¤èŒƒå›´å¯¹ä¸´åºŠå®è·µçš„è½¬åŒ–æ„ä¹‰ã€‚<br />
- ç™Œç—‡ç ”ç©¶ä¸ä¼ æ’­ï¼šå…³æ³¨ç™Œç—‡ç§‘å­¦ã€åˆ›æ–°ä»¥åŠç™Œç—‡ä¸å–œå‰§çš„è·¨ç•Œå¯¹è¯ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
- éšæœºã€å¼€æ”¾æ ‡ç­¾ã€å›½é™…ä¸‰æœŸä¸´åºŠç ”ç©¶è®¾è®¡ï¼Œä¸ºè‚ç™Œæ²»ç–—æä¾›é«˜çº§åˆ«è¯æ®ã€‚<br />
- ç¥ç»å¤–ç§‘æ‰‹æœ¯åˆ‡é™¤èŒƒå›´çš„é‡åŒ–ä¸ä¸´åºŠè½¬åŒ–ç ”ç©¶ã€‚</p>
<h3>ğŸ§ª åšå®¢æ›´æ–°</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
2026å¹´ä¼¦æ•¦åŸºå› ç»„ä¸ç”Ÿç‰©æ•°æ®èŠ‚å°†æ±‡èšæœ€å‰æ²¿çš„ç§‘å­¦ã€æŠ€æœ¯ä¸äººè„‰ï¼Œèšç„¦åŸºå› ç»„å­¦å’Œç”Ÿç‰©æ•°æ®é¢†åŸŸçš„æœ€æ–°è¿›å±•ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
- åŸºå› ç»„å­¦ç ”ç©¶<br />
- ç”Ÿç‰©æ•°æ®åˆ†æ<br />
- ä¸´åºŠåº”ç”¨åˆ›æ–°</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
- è·¨é¢†åŸŸäº¤æµä¸åˆä½œå¹³å°<br />
- æ¢ç´¢å‰æ²¿ç§‘å­¦æŠ€æœ¯</p>
            </div><h2>ğŸ“š åˆ†ç±»æµè§ˆ</h2>
<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ“° å…¬ä¼—å· (35æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰</h4>
<p><strong>1.</strong> â­ <strong>æœ€æ–°10+ç”Ÿä¿¡ï¼Œç©ºè½¬+å•ç»†èƒ+H3K18la ChIP-seq+CRISPR+bulkè½¬å½•ç»„ï¼Œå¤šç»„å­¦ç»å…¸å¥½æ–‡ï¼Œå€¼å¾—æ”¶è—ï¼</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡å°è¯¾å ‚<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šChIP-seqã€å•ç»†èƒã€è½¬å½•ç»„ã€ç”Ÿä¿¡<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šç‚¹å‡»æŸ¥çœ‹è¯¦æƒ…<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&amp;mid=2247504068&amp;idx=1&amp;sn=2e2f6cbfe2347550929544b689de7688" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> â­ <strong>ã€å‚ä¼šæé†’ã€‘åˆ©ç”¨å•ç»†èƒä¸ç©ºé—´å¤šç»„å­¦æ¢ç´¢å¾®ç”Ÿç‰©ç»„ä¸å…ç–«äº’ä½œæœºåˆ¶</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼š10x Genomics<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šå…ç–«ã€å¾®ç”Ÿç‰©ã€å•ç»†èƒã€ç©ºé—´ç»„å­¦<br />
- ğŸ“ <strong>æè¿°</strong>ï¼š11æœˆ26æ—¥ç›´æ’­ï¼Œä¸ä¸“å®¶å…±åŒæ­ç§˜ â€œå¦‚ä½•åˆ©ç”¨å•ç»†èƒä¸ç©ºé—´å¤šç»„å­¦æ¢ç´¢å¾®ç”Ÿç‰©ç»„ä¸å…ç–«äº’ä½œæœºåˆ¶â€ã€‚<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=MzU1MDk1NTY5MA==&amp;mid=2247541027&amp;idx=1&amp;sn=93e53ed520d8a7f10329f874489964ea" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> â­ <strong>æœ€æ–°10åˆ†ç”Ÿä¿¡ï¼Œå•ç»†èƒ+ç©ºè½¬å¤šç»„å­¦è¿›è¡Œä¸­æ€§ç²’ç»†èƒäºšå‹åˆ†æï¼Œè¯†åˆ« CTCF+TANï¼Œé¶å‘CTCFæ”¹å–„å…ç–«æ²»ç–—ç–—æ•ˆï¼</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡å°è¯¾å ‚<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šå…ç–«ã€å•ç»†èƒã€ç”Ÿä¿¡<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šç‚¹å‡»æŸ¥çœ‹è¯¦æƒ…<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&amp;mid=2247504068&amp;idx=5&amp;sn=17676606db045d7b6bcabfd7a0488d4e" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>4.</strong> â­ <strong>10æœˆæœ€æ–°26+ç”Ÿä¿¡ï¼Œå¤šç»„å­¦ç©ºé—´å…ç–«è°±åˆ†æç¡®å®šäº†ä¸‰çº§æ·‹å·´ç»“æ„ï¼ˆTLSï¼‰çš„äºšç¾¤å¹¶è¿›è¡Œæ·±å…¥åˆ†æï¼Œå»ºè®®æ”¶è—ï¼</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡å°è¯¾å ‚<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šå…ç–«ã€æ·‹å·´ã€ç”Ÿä¿¡<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šç‚¹å‡»æŸ¥çœ‹è¯¦æƒ…<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&amp;mid=2247504068&amp;idx=3&amp;sn=b7ff58629c7d764112a4c1721968915e" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>5.</strong> â­ <strong>æœ€æ–°8+ç”Ÿä¿¡ï¼Œå¤šç»„å­¦è¯†åˆ«ä¸‰çº§æ·‹å·´ç»“æ„ï¼ˆTLSï¼‰ç»“æ„å¹¶è¿›è¡Œé’ˆå¯¹æ€§åˆ†æã€‚é¢„æµ‹é¢„ååŠå…ç–«æ²»ç–—ç–—æ•ˆï¼Œå€¼å¾—å€Ÿé‰´ï¼</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡å°è¯¾å ‚<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šå…ç–«ã€æ·‹å·´ã€ç”Ÿä¿¡<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šç‚¹å‡»æŸ¥çœ‹è¯¦æƒ…<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&amp;mid=2247504068&amp;idx=2&amp;sn=79cb771915f774099f30eae6af65c829" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>6.</strong> â­ <strong>å•ç»†èƒ+ç©ºè½¬+ä»£è°¢ç»„ï¼Œå…¬å¼€æ•°æ®é›†æ‰¾å‡ºäº®ç‚¹å°±èƒ½å‘1åŒº12åˆ†</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡äºº<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šä»£è°¢ã€ä»£è°¢ç»„ã€å•ç»†èƒ<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651248818&amp;idx=8&amp;sn=11df37e0b4894d272c6da864a67d8573" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>7.</strong> â­ <strong>Cancer Cellé‡ç£…ï¼šè‚¿ç˜¤ç«Ÿè¢«è‡ªå·±äººèƒŒåˆºï¼çªå˜å¼•çˆ†å…ç–«æ²»ç–—</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡äºº<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šè‚¿ç˜¤ã€cancerã€å…ç–«<br />
- ğŸ“ <strong>æè¿°</strong>ï¼š10æœˆ16æ—¥ï¼ŒCancer Cellå‘è¡¨äº†å¾·å·å¤§å­¦MDå®‰å¾·æ£®ç™Œç—‡ä¸­å¿ƒPadmanee Sharmaæ•™æˆå›¢é˜Ÿçš„é‡<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651248818&amp;idx=3&amp;sn=2a28fd3db9ace259564e4294c2ea7a1c" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>8.</strong> â­ <strong>çœ‹çœ‹NCç”Ÿä¿¡ä¸ºä¸»çš„æ–‡ç« éœ€è¦å¤šå°‘å·¥ä½œé‡ï¼Œå•ç»†èƒå¤šç»„å­¦åˆ†æå­¦ä¹ ã€‚å‘ç° IDH1 æŠ‘åˆ¶å‰‚å¯é€†è½¬é«“æ¯ç»†èƒç˜¤æ”¾ç–—è€è¯</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡é’±åŒå­¦<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šè€è¯ã€å•ç»†èƒã€ç”Ÿä¿¡<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šç”Ÿä¿¡æ–‡ç« å­¦ä¹ <br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=MzkwMzY2NjkwNg==&amp;mid=2247495727&amp;idx=1&amp;sn=a703f13586da1d4d7fa702a45cb0560e" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>9.</strong> <strong>pH/ROSå“åº”å¾®é’ˆé‡å¡‘å·¨å™¬ç»†èƒçº¿ç²’ä½“åŠŸèƒ½</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šåŒåŒ»æµäº‘Medfocus<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šå·¨å™¬ç»†èƒã€çº¿ç²’ä½“<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šâ€œä»£è°¢å…ç–«é‡ç¼–ç¨‹â€ç­–ç•¥ï¼Œé€šè¿‡çº§è”é¶å‘å¾®é’ˆç²¾å‡†è°ƒæ§å·¨å™¬ç»†èƒçº¿ç²’ä½“ä»£è°¢ï¼Œå®ç°äº†ç³–å°¿ç—…åˆ›é¢çš„æ— ç˜¢ç—•æ„ˆåˆã€‚<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=Mzk3NTY2NDk1Nw==&amp;mid=2247488308&amp;idx=1&amp;sn=3e4910c028314a53cc716f48ad36d63b" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>10.</strong> <strong>æ‰¬å·å¤§å­¦å›¢é˜Ÿèšç„¦â€œè‚ è„‘è½´â€ç²¾å‡†ä¸Šåˆ†ï¼è¿™å¥—èŒç¾¤å˜åŒ–-ä»£è°¢ç‰©æ”¹å˜-é€šè·¯è°ƒæ§çš„æ€è·¯ï¼Œå€¼å¾—æ¨æ•²ï¼</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šç¥ç»å²›<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šä»£è°¢ã€é€šè·¯<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=MzkyNzcxMjEyMg==&amp;mid=2247498015&amp;idx=1&amp;sn=9c1867076da46b8508ff9cea504d36c5" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<blockquote>
<p>ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 25 æ¡å†…å®¹ï¼Œè¯¦è§ <a href="#æ›´å¤š-å…¬ä¼—å·">æ–‡æœ«</a></p>
</blockquote>
</div>
</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§¬ æ•°æ®å‰æ²¿ (44æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰</h4>
<p><strong>1.</strong> â­ <strong>GSE301957 å…±é¶å‘ EZH2 å’Œ TEAD é€šè¿‡ Hippo é€šè·¯çªå˜ç™Œç—‡ä¸­çš„è‚¿ç˜¤å›ºæœ‰å…ç–«ä¿¡å·é€šè·¯è¯±å¯¼ç»†èƒå‡‹äº¡ - æ¥è‡ª EZH2 åŸºå› ç ´åçš„ RNA-seq æ•°æ®</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€immuneã€RNA-seqã€pathway<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Antja-Voy Hartley ; Zhaorong Li ; Matthew Booker ; Nicholas Tourtillot ; Pasi A JÃ¤nneSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensTEA/TEF-domain [TEAD] inhibitors are being evaluated in clinical trials for cancers with alterations in the Hippo pathway including mesothelioma. We recently developed and showcased the potency of TEAD palmitoylation inhibitors MYF-03-69 and MYF-03-176 in mesothelioma cell lines. However, TEAD inhibition results in cell cycle arrest in cell line models with Hippo pathway alterations without inducing cell death, potentially limiting their long-term clinical efficacy. Using a genome-wide CRISPR/Cas9 screen, we identified EZH2 as a critical modulator of the cellular response to TEAD inhibition. Compared to single agent treatments, EZH2i/TEADi robustly triggered apoptosis and suppressed the growth of Hippo-mutated cells in vitro and in vivo. Mechanistically, EZH2i/TEADi-treated cells exhibited heightened activation of tumor-intrinsic innate immune signaling which resulted in DNA damage and subsequent apoptosis. Taken together, we propose this novel combinatorial strategy as a potential approach to enhancing the anti-tumor efficacy of single agent TEAD targeting therapies in Hippo pathway altered tumors. This GEO accession includes the data series associated with RNA-seq derived from pharmacologic disruption of EZH2.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE301957" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> â­ <strong>GSE289248 å¤šæ¢³æŠ‘åˆ¶å¤åˆç‰© 2 ä¸ DNA ç”²åŸºåŒ–ä¹‹é—´çš„ä¸²æ‰°ä»‹å¯¼ç¥ç»å†…åˆ†æ³Œå‰åˆ—è…ºç™Œè°±ç³»å¯å¡‘æ€§ [RNA-Seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€RNA-seqã€methylation<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Richa Singh ; David S RickmanSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusAcquired changes in DNA methylation have been proposed as a mechanism underlying epigenetic plasticity in several cancer types. In prostate cancer, methylation changes are dynamic, with preclinical studies pointing to a tumor suppressor role of the DNA methyltransferase DNMT1 in early stage, in contrast to an oncogenic function of DNMT1 in later stage. The importance of DNA methylation dynamics during normal development and cell lineage fate decisions also points to DNA methylation having a critical function in lineage plasticity, yet the mechanisms by which DNA methylation changes drives lineage transitions in prostate cancer is not well understood. DNA methylation can directly repress gene expression but also cooperate with other epigenetic pathways to modulate downstream transcriptional activity. The enhancer of zeste homolog 2 (EZH2) protein is a subunit of the polycomb repressive complex 2 (PRC2) and catalyzer of the repressive histone 3 lysine 27 tri-methylation (H3K27me3) mark that also acts to suppress downstream transcriptional activity and has also been implicated in lineage plasticity. EZH2 is overexpressed in castration-resistant prostate cancer (CRPC) including NEPC and is an emerging therapeutic target. Although, the compensatory relationship between DNA methylation and EZH2 has been shown in embryonic stem cell studies and in some cancer types during acquired treatment resistance or immune evasion, how DNA methylation and EZH2/PRC2 interact to modulate prostate cancer lineage plasticity has not been characterized. In this study, we address the potential crosstalk between epigenetic pathways in advanced prostate cancer and demonstrate how DNA methylation and H3K27me3 profiles overlap and cooperate to reprogram the epigenome during prostate cancer lineage plasticity. Using both mouse and patient-derived models, we highlight the compensatory roles of these two repressive machineries during progression of CRPC towards a NE-lineage state. We predict their specific impact on NEPC progression by assessing the associated molecular alterations following genetic and pharmacological perturbations of each.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE289248" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> â­ <strong>GSE289247 å¤šæ¢³æŠ‘åˆ¶å¤åˆç‰© 2 ä¸ DNA ç”²åŸºåŒ–ä¹‹é—´çš„ä¸²æ‰°ä»‹å¯¼ç¥ç»å†…åˆ†æ³Œå‰åˆ—è…ºç™Œè°±ç³»å¯å¡‘æ€§ [ChIP-Seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€ChIP-seqã€methylation<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Richa Singh ; David S RickmanSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Homo sapiens ; Mus musculusAcquired changes in DNA methylation have been proposed as a mechanism underlying epigenetic plasticity in several cancer types. In prostate cancer, methylation changes are dynamic, with preclinical studies pointing to a tumor suppressor role of the DNA methyltransferase DNMT1 in early stage, in contrast to an oncogenic function of DNMT1 in later stage. The importance of DNA methylation dynamics during normal development and cell lineage fate decisions also points to DNA methylation having a critical function in lineage plasticity, yet the mechanisms by which DNA methylation changes drives lineage transitions in prostate cancer is not well understood. DNA methylation can directly repress gene expression but also cooperate with other epigenetic pathways to modulate downstream transcriptional activity. The enhancer of zeste homolog 2 (EZH2) protein is a subunit of the polycomb repressive complex 2 (PRC2) and catalyzer of the repressive histone 3 lysine 27 tri-methylation (H3K27me3) mark that also acts to suppress downstream transcriptional activity and has also been implicated in lineage plasticity. EZH2 is overexpressed in castration-resistant prostate cancer (CRPC) including NEPC and is an emerging therapeutic target. Although, the compensatory relationship between DNA methylation and EZH2 has been shown in embryonic stem cell studies and in some cancer types during acquired treatment resistance or immune evasion, how DNA methylation and EZH2/PRC2 interact to modulate prostate cancer lineage plasticity has not been characterized. In this study, we address the potential crosstalk between epigenetic pathways in advanced prostate cancer and demonstrate how DNA methylation and H3K27me3 profiles overlap and cooperate to reprogram the epigenome during prostate cancer lineage plasticity. Using both mouse and patient-derived models, we highlight the compensatory roles of these two repressive machineries during progression of CRPC towards a NE-lineage state. We predict their specific impact on NEPC progression by assessing the associated molecular alterations following genetic and pharmacological perturbations of each.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE289247" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>4.</strong> â­ <strong>GSE286958 å‰åˆ—è…ºè…ºç™Œå’Œç¥ç»å†…åˆ†æ³Œå‰åˆ—è…ºç™Œæ¨¡å‹çš„è¡¨è§‚é—ä¼ å­¦åˆ†æï¼Œä»¥äº†è§£DNMT-EZH2çš„ç›¸äº’ä½œç”¨ã€‚[RNA-Seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€RNA-seqã€epigenetic<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Venkadakrishnan Varadha Balaji ; Beltran HimishaSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensEZH2-DNMT crosstalk is diverse across prostate adenocarcinoma and neuroendocrine prostate cancer.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE286958" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>5.</strong> â­ <strong>GSE310915 æŸ“è‰²è´¨å¯åŠæ€§å’Œè½¬å½•ç»„å­¦çš„å•ç»†èƒæ•´åˆæ­ç¤ºåµå·¢è‚¿ç˜¤æµ¸æ¶¦é€‚åº”æ€§NKç»†èƒçš„è°ƒæ§ç½‘ç»œ</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€single-cellã€transcriptomics<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Yizhe Sun ; Meng Wan ; Solrun Kolbeinsdottir ; Kang Wang ; Shruti Khare ; Okan Gultekin ; Sahar Salehi ; Kaisa Lehti ; Ramanuj Dasgupta ; Theodoros Foukakis ; Martin Enge ; Dhifaf SarhanSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensNatural killer (NK) cells are traditionally recognized for their rapid, non-specific responses against virus-infected or malignantly transformed cells, functioning as key effectors of innate immunity. However, a distinct subset known as adaptive NK (aNK) cells has been shown to acquire memory-like properties following viral infections, indicating their capacity for antigen-specific immune recall. Intriguingly, aNK cells have also been identified within the tumor microenvironment, where they can mediate tumor-specific recall responses. Yet, the regulatory mechanisms managing their function in tumor-infiltrating aNK cells remain largely unknown. In this study, we integrated publicly available multiomics datasets from ovarian cancer, including single-cell chromatin accessibility (scATAC-seq) and single-cell RNA sequencing (scRNA-seq), to identify chromatin-accessible regions and construct transcription factors (TF)-gene regulatory networks. To validate and extend these findings, we performed Smart-seq3 on NK cells isolated from ovarian tumors and applied SCENIC analysis to identify TF-driven gene regulation. By integrating results from both analyses, we identified PRDM1 and STAT2 as key TFs, along with their downstream targets CRCP and MTFP1, specifically enriched in tumor-infiltrating aNK cells. The expression levels of CRCP and MTFP1 positively correlated with NK cell infiltration in ovarian cancer tissues, suggesting their potential functions in supporting tumor-specific NK cell memory responses. In addition, external validation using data from the PROMIX clinical trial demonstrated that PRDM1 and STAT2 expression levels are positively associated with both overall survival and aNK cell-associated transcriptional features.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310915" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>6.</strong> â­ <strong>GSE293929 IPSCè¡ç”Ÿçš„CAR-NKç»†èƒå¤–å›Šæ³¡é‡å¡‘å·¨å™¬ç»†èƒå…ç–«å¹¶å¢å¼ºè‚¿ç˜¤æ¸…é™¤</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€immunityã€macrophage<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Hao Zhang ; Peng Xia ; Bin Jin ; Minghe Zhang ; Jie LiuSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusChimeric antigen receptor (CAR) cell therapy has revolutionized the treatment of hematological malignancies; however, its efficacy in solid tumors remains limited due to dense stromal barriers and the immunosuppressive tumor microenvironment (TME), which hinder immune cell infiltration and persistence. To overcome these challenges, we propose an innovative strategy utilizing induced pluripotent stem cell (iPSC)-derived CAR-NK extracellular vesicles (CAR-iNEV), engineered from iPSC-differentiated NK cells. Unlike conventional CAR-NK cell therapies that rely on immortalized NK92 cell lines, our approach leverages iPSC-derived NK cells, reducing tumorigenic risk and enhancing CAR transduction efficiency. Additionally, we incorporate nanobody-based CAR constructs in place of traditional single-chain variable fragments (scFv), significantly improving CAR stability and expression efficiency. Beyond direct cytotoxicity, CAR-iNEV offers superior therapeutic advantages, including reduced systemic toxicity and enhanced drug delivery capabilities compared to CAR-iNK cells. In vivo studies demonstrate that CAR-iNEV exhibits exceptional safety and potent antitumor activity across multiple solid tumor xenograft and patient-derived xenograft (PDX) models in humanized mice. Mechanistically, CAR-iNEV not only directly eliminates tumor cells but also reprograms the TME by activating macrophage-derived nitric oxide synthase (NOS2), amplifying host antitumor immunity. These findings establish CAR-iNEV as a promising platform for solid tumor immunotherapy, particularly in relapsed and metastatic settings, providing a novel and effective strategy that bridges direct tumor targeting with immune microenvironment remodeling. This study lays the foundation for future clinical translation, advancing the next generation of cell-free CAR-based immunotherapies.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE293929" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>7.</strong> â­ <strong>GSE221608 CRCæ‚£è€…æ­£å¸¸è‚ é»è†œç»„ç»‡ã€é…å¯¹çš„åŸå‘æ€§CRCç»„ç»‡å’Œè‚è½¬ç§»ç—…ç¶çš„è½¬å½•ç»„æµ‹åº</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šsequencingã€transcriptomeã€regex:intestin(e|al)<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Wen Ni ; Su Yao ; Jianming LiSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensTo investigate the key regulators in CRC progression, we carried out transcriptome sequencing in normal intestinal mucosal tissues, paired primary CRC tissues and liver metastases lesions in participants of CRC.We then performed gene expression profiling analysis using data obtained from RNA-seq of tissues.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE221608" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>8.</strong> <strong>GSE311014 ç»†èƒå› å­é©±åŠ¨çš„ç³–é˜è„‚ä»£è°¢è°ƒèŠ‚åŸä»£äººè‚¾å°çƒç³»è†œç»†èƒå†…è´¨ç½‘é’™ç¨³æ€</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcytokineã€metabolism<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Mariia Stefanenko ; Tessa M Ortiz ; Sandra G Mungaray ; Mykhailo Fedoriuk ; Oleg Palygin ; Stefano Berto ; Drew Moore ; Tamara K NowlingSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensGlycosphingolipids (GSLs), including hexosylceramides (HexCers), lactosylceramides (LacCers), and gangliosides composed of one or more sugar residues attached to ceramide, are essential components of cell membranes. Dysregulated GSL metabolism has been implicated in various inflammatory and autoimmune diseases, including lupus nephritis; however, its contribution to renal cell dysfunction remains largely unexplored. In this study, we demonstrate that in primary human renal mesangial cells (hRMCs), proinflammatory cytokines relevant to lupus elicit significant upregulation and secretion of inflammatory mediators that parallel intracellular and extracellular accumulation of HexCers and elevated cytosolic calcium (Ca2+) levels. The increase in cytosolic Ca2+ was attributed to a decrease in endoplasmic reticulum (ER) Ca2+ store capacity. Pharmacological inhibition of GSL synthesis with eliglustat significantly reduced HexCers levels and restored ER Ca2+ stores, but did not impact cytokine-induced cytokine/chemokine secretion or cell viability/proliferation. Together, these data suggest that elevated GSL synthesis modulates cytokine-induced ER CaÂ²âº dysregulation in mesangial cells and may play a role in the pathogenesis of lupus nephritis.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311014" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>9.</strong> <strong>GSE295902 EBF1 å’Œ PAX5 å¯¹ T ç»†èƒè°±ç³»æ½œèƒ½å‘æŒ¥å‰‚é‡ä¾èµ–æ€§çš„è¡¨è§‚é—ä¼ æŠ‘åˆ¶ä½œç”¨ [ATAC-seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šATAC-seqã€epigenetic<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Johanna Tingvall-Gustafsson ; Kim Hellerstedt ; Jonas UngerbÃ¤ck ; Mikael SigvardssonSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Mus musculusB-lymphocyte development is dependent on the coordinated action of transcription factors controlling the expression of stage and lineage specific genes. To better understand gene regulation and changes in the epigenetic landscape in early B-cell development, we conducted combined SC-RNA/ATAC seq analysis of bone marrow progenitor populations, allowing us to build a developmental trajectory based on changes in epigenetic accessibility. This analysis identified a rapid shift in DNA accessibility, where T-lineage primed progenitors gained the epigenetic landscape of B-lymphocytes. The epigenetic switch correlated well with initiation of EBF1 and PAX5 transcription as well as their functional activity. As ectopic expression of EBF1 in Pax5-/- pro-B cells was not sufficient to mediate either the full activation of the B-lineage program of silencing of T-lineage associated genes, we conclude that PAX5 and EBF1 are independently essential for the establishment of the epigenetic landscape in normal B-cell development. This idea was supported by the finding that pro-B cells from mice with combined heterozygote deletion of the Ebf1 and Pax5 genes, carried a non-differentiated epigenetic landscape and expressed T-lineage associated genes. The importance of epigenetic silencing for the preservation of B-cell fate was supported by the finding that inhibition of the histone methylases EZH1 and EZH2 in pro-B cells, allowed for the activation of T-lineage genes and generation of T-lineage cells in response to Notch signaling. Hence, B-lymphoid commitment is associated with a transcription factor dose dependent epigenetic switch, silencing an inherent T-lineage potential in early lymphoid progenitors.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE295902" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>10.</strong> <strong>GSE295900 EBF1 å’Œ PAX5 å¯¹ T ç»†èƒè°±ç³»æ½œèƒ½å‘æŒ¥å‰‚é‡ä¾èµ–æ€§çš„è¡¨è§‚é—ä¼ æŠ‘åˆ¶ä½œç”¨ [RNA-seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šRNA-seqã€epigenetic<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Johanna Tingvall-Gustafsson ; Kim Hellerstedt ; Jonas UngerbÃ¤ck ; Mikael SigvardssonSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusB-lymphocyte development is dependent on the coordinated action of transcription factors controlling the expression of stage and lineage specific genes. To better understand gene regulation and changes in the epigenetic landscape in early B-cell development, we conducted combined SC-RNA/ATAC seq analysis of bone marrow progenitor populations, allowing us to build a developmental trajectory based on changes in epigenetic accessibility. This analysis identified a rapid shift in DNA accessibility, where T-lineage primed progenitors gained the epigenetic landscape of B-lymphocytes. The epigenetic switch correlated well with initiation of EBF1 and PAX5 transcription as well as their functional activity. As ectopic expression of EBF1 in Pax5-/- pro-B cells was not sufficient to mediate either the full activation of the B-lineage program of silencing of T-lineage associated genes, we conclude that PAX5 and EBF1 are independently essential for the establishment of the epigenetic landscape in normal B-cell development. This idea was supported by the finding that pro-B cells from mice with combined heterozygote deletion of the Ebf1 and Pax5 genes, carried a non-differentiated epigenetic landscape and expressed T-lineage associated genes. The importance of epigenetic silencing for the preservation of B-cell fate was supported by the finding that inhibition of the histone methylases EZH1 and EZH2 in pro-B cells, allowed for the activation of T-lineage genes and generation of T-lineage cells in response to Notch signaling. Hence, B-lymphoid commitment is associated with a transcription factor dose dependent epigenetic switch, silencing an inherent T-lineage potential in early lymphoid progenitors.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE295900" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<blockquote>
<p>ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 34 æ¡å†…å®¹ï¼Œè¯¦è§ <a href="#æ›´å¤š-æ•°æ®å‰æ²¿">æ–‡æœ«</a></p>
</blockquote>
</div>
</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ”¬ æœŸåˆŠæ–‡ç«  (4æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨4æ¡ï¼‰</h4>
<p><strong>1.</strong> <strong>Camrelizumab åŠ  rivoceranib ä¸ sorafenib ä½œä¸ºä¸å¯åˆ‡é™¤è‚ç»†èƒç™Œï¼ˆCARES-310ï¼‰çš„ä¸€çº¿æ²»ç–—ï¼šä¸€é¡¹éšæœºã€å¼€æ”¾æ ‡ç­¾ã€å›½é™…ä¸‰æœŸä¸´åºŠç ”ç©¶çš„æœ€ç»ˆåˆ†æ</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šBç»†èƒ<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext:<br />
- ğŸ”— <a href="https://m.x-mol.com/paper/1993375579267772416/t" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> <strong>ç™Œç—‡é©å‘½ï¼šç§‘å­¦ã€åˆ›æ–°ä¸å¸Œæœ›</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šç™Œç—‡<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext:<br />
- ğŸ”— <a href="https://m.x-mol.com/paper/1993378347768459264/t" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> <strong>ç™Œç—‡ä¸å–œå‰§ï¼šä¸‰åœºå•å£å–œå‰§ç‰¹åˆ«èŠ‚ç›®å›é¡¾</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šç™Œç—‡<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext:<br />
- ğŸ”— <a href="https://m.x-mol.com/paper/1993381112259391488/t" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>4.</strong> <strong>IDH çªå˜èƒ¶è´¨ç˜¤ç¥ç»å¤–ç§‘åˆ‡é™¤èŒƒå›´å¢åŠ ï¼šè½¬åŒ–ä¸ºæ ‡å‡†å®è·µçš„é—®é¢˜</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šç¥ç»<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext:<br />
- ğŸ”— <a href="https://m.x-mol.com/paper/1993364037818232832/t" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
</div>
</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§ª åšå®¢æ›´æ–° (1æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨1æ¡ï¼‰</h4>
<p><strong>1.</strong> <strong>ä¼¦æ•¦åŸºå› ç»„å­¦ä¸ç”Ÿç‰©æ•°æ®èŠ‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šgenomics<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šThe Festival of Genomics and Biodata 2026 offers two days of cutting edge science, technology and networking, bringing together researchers, clinicians and innovators across more than sixteen content theatres...<br />
- ğŸ”— <a href="https://www.rna-seqblog.com/the-festival-of-genomics-biodata-in-london/" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
</div>
</details>

<h2>ğŸ“Š å…³é”®è¯ç»Ÿè®¡</h2>
<table class="keywords-table">
<thead>
<tr>
<th>å…³é”®è¯</th>
<th>å‡ºç°æ¬¡æ•°</th>
</tr>
</thead>
<tbody>
<tr>
<td>cancer</td>
<td>12</td>
</tr>
<tr>
<td>RNA-seq</td>
<td>10</td>
</tr>
<tr>
<td>ç”Ÿä¿¡</td>
<td>8</td>
</tr>
<tr>
<td>å…ç–«</td>
<td>7</td>
</tr>
<tr>
<td>epigenetic</td>
<td>7</td>
</tr>
<tr>
<td>transcriptome</td>
<td>7</td>
</tr>
<tr>
<td>å•ç»†èƒ</td>
<td>6</td>
</tr>
<tr>
<td>Tç»†èƒ</td>
<td>5</td>
</tr>
<tr>
<td>methylation</td>
<td>4</td>
</tr>
<tr>
<td>æ·‹å·´</td>
<td>3</td>
</tr>
<tr>
<td>é€šè·¯</td>
<td>3</td>
</tr>
<tr>
<td>è€è¯</td>
<td>3</td>
</tr>
<tr>
<td>tumor</td>
<td>3</td>
</tr>
<tr>
<td>è‚¿ç˜¤</td>
<td>3</td>
</tr>
<tr>
<td>leukemia</td>
<td>3</td>
</tr>
<tr>
<td>çº¿ç²’ä½“</td>
<td>2</td>
</tr>
<tr>
<td>ä»£è°¢</td>
<td>2</td>
</tr>
<tr>
<td>ChIP-seq</td>
<td>2</td>
</tr>
<tr>
<td>metabolism</td>
<td>2</td>
</tr>
<tr>
<td>Bç»†èƒ</td>
<td>2</td>
</tr>
</tbody>
</table>
<hr />
<h2>ğŸ“ æ›´å¤šå†…å®¹</h2>
<details>
<summary><a name="æ›´å¤š-å…¬ä¼—å·"></a>ğŸ“° å…¬ä¼—å· å…¶ä»–å†…å®¹ (25æ¡)</summary>
<div class="details-content">
<ul>
<li><a href="https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&amp;mid=2247504068&amp;idx=4&amp;sn=2eb56be1c84c35980ed88772fe507ddd" target="_blank" rel="noopener noreferrer">æœ€æ–°8åˆ†ç”Ÿä¿¡ï¼Œç©ºè½¬å¤šç»„å­¦åˆ†ææ­ç¤ºCAF-ç™Œç»†èƒé€šè®¯ä»‹å¯¼ PARPi è€è¯çš„å…¨æ–°æœºåˆ¶ï¼Œå†…å®¹å¾ˆå°‘ï¼Œä¼˜åŠ¿åœ¨äºè‡ªæµ‹æ•°æ®ï¼</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzI4ODc5MDI5NA==&amp;mid=2247503578&amp;idx=1&amp;sn=75967d869354773ae42eda1c0cfe122f" target="_blank" rel="noopener noreferrer">ã€Šè‡ªç„¶ã€‹ï¼šè‚ ç™Œé â€œå˜èº«â€é€ƒç”Ÿï¼ç§‘å­¦å®¶é¦–æ¬¡è¯å®ï¼Œè‚ ç™Œå¯åˆ©ç”¨ä¸Šçš®ç»†èƒå¯å¡‘æ€§å¯¹MAPKé€šè·¯æŠ‘åˆ¶å‰‚è€è¯</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzAxMDkxODM1Ng==&amp;mid=2247547209&amp;idx=1&amp;sn=0daa49c33e9aa7f357c4c9bd5c281039" target="_blank" rel="noopener noreferrer">pythonå•ç»†èƒå­¦ä¹ ï¼ˆä¸‰ï¼‰ï¼šbatch2æ•°æ®è¯»å–ä¸å¤„ç†</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzkzODIxMDY5NQ==&amp;mid=2247507637&amp;idx=3&amp;sn=a905d162ab36a0f644bb784dc1a8cb33" target="_blank" rel="noopener noreferrer">Nature Genetics | ç»ˆç»“å˜å¼‚è‡´ç—…æ€§è¯„åˆ†â€œé€šèƒ€â€ï¼é¦–ä¸ªå…¨è›‹ç™½è´¨ç»„æ ¡å‡†æ¨¡å‹popEVEé‡å¡‘è‡´ç—…æ€§é¢„æµ‹æ ‡å‡†</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651248818&amp;idx=5&amp;sn=b64f36971667d64dbb34427033cc3f21" target="_blank" rel="noopener noreferrer">é¡¶åˆŠé‡Œç¨‹ç¢‘çªç ´ï¼å“ˆä½›å›¢é˜Ÿç»˜ 170 ä¸‡ T ç»†èƒå›¾è°±ï¼Œç”Ÿä¿¡æ³¨é‡Šæœ‰äº† â€œé»„é‡‘æ ‡å°ºâ€</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MjM5MzQ4NTk4MA==&amp;mid=2656510953&amp;idx=4&amp;sn=cd1def5c8c6e8814e6d77c9989dd1ec6" target="_blank" rel="noopener noreferrer">æ–°è§’è‰²ï¼é‡åº†å¤§å­¦é™„å±è‚¿ç˜¤åŒ»é™¢å‘æ–‡ï¼šICIså…ç–«æ²»ç–—çš„æ½œåœ¨è”åˆæ²»ç–—é¶ç‚¹</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzU1MzMxMzcyMg==&amp;mid=2247790821&amp;idx=2&amp;sn=5a2a37ffe0da89b24e2252f4b7ca23c6" target="_blank" rel="noopener noreferrer">Cell Stem Cellï¼šé€†è½¬æº¶é…¶ä½“åŠŸèƒ½éšœç¢ï¼Œè®©è¡°è€é€ è¡€å¹²ç»†èƒæ¢å¤å¹´è½»æ€</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=Mzg2OTU2MzM2NA==&amp;mid=2247493044&amp;idx=1&amp;sn=66969bddc7b4240a5fd0b5f88486bf17" target="_blank" rel="noopener noreferrer">åˆšåˆšå‘è¡¨çš„7.5åˆ†ç”Ÿä¿¡ï¼Œä¸€ç§ç”¨äºç²¾å‡†æ³›ç™Œåˆ†ç±»çš„å¤šè¡¨å¾æ·±åº¦å­¦ä¹ æ¡†æ¶ï¼åªè¦æœ‰æŠ€æœ¯ï¼Œè¿˜åšä»€ä¹ˆå®éªŒï¼</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzYyNDMwNjg3Nw==&amp;mid=2247484117&amp;idx=1&amp;sn=391bedbf530054bf63cfb4dfa9aabfc6" target="_blank" rel="noopener noreferrer">æ·‹å·´å¾ªç¯ï¼ˆå»ºè®®æ”¶è—ï¼‰</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzI5MDQzNjY2OA==&amp;mid=2247569157&amp;idx=2&amp;sn=b9322143614e453c9f349cb66115fb2e" target="_blank" rel="noopener noreferrer">ä»å¿ƒæ¢—åˆ°å…¨èº«ç‚ç—‡ï¼Œéƒ½æŒ‡å‘åŒä¸€å…³é”®è›‹ç™½ï¼é¶å‘è¯ç‰©æœ‰æœ›æ”¹å†™æ²»ç–—æ ¼å±€</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzU0ODQyNjQxOA==&amp;mid=2247555219&amp;idx=2&amp;sn=fd9a3eb054b683b9582983f92008c644" target="_blank" rel="noopener noreferrer">Sci Tra Med | å®éªŒæ€§èƒ¶è´¨æ¯ç»†èƒç˜¤è¯•éªŒç»“æœæœ‰æœ›æ¨åŠ¨æ‚£è€…ç›‘æµ‹ä¸ç–—æ³•çš„é©æ–°</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzU0ODQyNjQxOA==&amp;mid=2247555219&amp;idx=1&amp;sn=ec9f0298a517f2f715dcc8a4b14c62ad" target="_blank" rel="noopener noreferrer">Nat Biotech | æœ€æ–°è‚¿ç˜¤èŠ¯ç‰‡æŠ€æœ¯ï¼šåŠ©åŠ›å®ä½“ç˜¤CAR-Tç–—æ³•ç ”å‘</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=Mzg2OTczNjI0OQ==&amp;mid=2247529067&amp;idx=1&amp;sn=3b2ce9fe982f69c25d756186fcc17ae3" target="_blank" rel="noopener noreferrer">å“ªå®¶å…¬å¸èƒ½è£ç™»é«˜å¼•ç»†èƒå› å­å›½äº§ç¬¬ä¸€ï¼Ÿ</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=Mzg2NTE1MzU4NQ==&amp;mid=2247523470&amp;idx=1&amp;sn=eaa08e109ddfa60c5cf96e3bfcfb9bc6" target="_blank" rel="noopener noreferrer">ä¸­å›½ç§‘å­¦é™¢åŒ—äº¬åŸºå› ç»„ç ”ç©¶æ‰€éƒäºšé™å›¢é˜Ÿè¯šæ‹›ç‰¹åˆ«ç ”ç©¶åŠ©ç†ï¼ˆåšå£«åï¼‰</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651248818&amp;idx=7&amp;sn=8969a46e4815ff49bb16b476c894b644" target="_blank" rel="noopener noreferrer">Natureï¼šscWGS+scRNAè§£å¯†å…¨åŸºå› ç»„å€å¢çš„æ¼”åŒ–åŠ¨æ€</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651248818&amp;idx=4&amp;sn=d6e97f1b3e8a7d29b6ccd973803e3b36" target="_blank" rel="noopener noreferrer">åˆ«å‚»äº†ï¼å¤šç»„å­¦åªåšå…³è”å’Œé€šè·¯ï¼Ÿè¿™æ³¢è¡€äºï¼</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651248818&amp;idx=2&amp;sn=1eb33102d6f16b04517c0d956730aef4" target="_blank" rel="noopener noreferrer">è…¾è®¯ç™»26.6åˆ†Natureå­åˆŠï¼Œåªæœ‰ä½ æƒ³ä¸åˆ°çš„è›‹ç™½è´¨ï¼æ²¡æœ‰è¿™ä¸ªæ¨¡å‹é¢„æµ‹ä¸äº†çš„</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzU5MDcwNzg0MA==&amp;mid=2247659415&amp;idx=2&amp;sn=67bb782fa7826cdeab4f004af7f64e6e" target="_blank" rel="noopener noreferrer">æœºä½“ç¨³æ€çš„å…ç–«è°ƒèŠ‚â€”â€”è‹å†°æ•™æˆä¸Immunityå¯¹è¯å½• | Cell Symposiaæ‘˜è¦å¾é›†ä¸­</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzUxMzk5MjY5NA==&amp;mid=2247650773&amp;idx=2&amp;sn=7075a84eec2b46ec4cf1ea4d75bcda95" target="_blank" rel="noopener noreferrer">ä¸ºçœç»è´¹ï¼Œå¯¼å¸ˆå–Šå¤§å®¶æ‰‹æ“æŠ—ä½“ï¼Ÿä½†æˆ‘ä¸¤ä¸ªæœˆéƒ½æ²¡æ‹¿åˆ°é˜³æ€§å…‹éš†</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzUxMzk5MjY5NA==&amp;mid=2247650773&amp;idx=1&amp;sn=1045376fce5df2679b210024ef1e2bbd" target="_blank" rel="noopener noreferrer">æˆåŠŸé€†è½¬è€å¹´ç—´å‘†ï¼å››å·å¤§å­¦åè¥¿åŒ»é™¢å‘ç°ï¼šæ³¨å°„ 2 å°æ—¶ï¼Œæ¸…é™¤è¿‘ 50% å¤§è„‘ã€Œåƒåœ¾ã€ï¼Œè®°å¿†æ¢å¤æŒç»­åŠå¹´</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MjM5MzQ4NTk4MA==&amp;mid=2656510953&amp;idx=1&amp;sn=bde7ad9bca478cda3596cf4b2821dfba" target="_blank" rel="noopener noreferrer">ä¸´åºŠè¯•éªŒç»“æœå‘å¸ƒï¼åŒ—äº¬åå’ŒåŒ»é™¢æ›¾å°å³°å›¢é˜Ÿé¢†è¡”æ–°å‹æŠ—CD38å•å…‹éš†æŠ—ä½“åœ¨ç³»ç»Ÿæ€§çº¢æ–‘ç‹¼ç–®æ²»ç–—ä¸­è¡¨ç°å‡ºè‰¯å¥½å®‰å…¨æ€§å’Œæ˜¾ç€ç–—æ•ˆ</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=Mzg5NjgxNjkwOA==&amp;mid=2247503146&amp;idx=2&amp;sn=0a9523fcf992b9580c2d83231dc0a223" target="_blank" rel="noopener noreferrer">è„‘ç§‘å­¦ | Nature | å…¨çš®å±‚åŸä½æµ‹åºæ­ç¤ºè¾“å…¥ä¾èµ–çš„åŒºåŸŸèº«ä»½</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=Mzg5NjgxNjkwOA==&amp;mid=2247503146&amp;idx=1&amp;sn=198def38ad29902f15ac1b4332071f5e" target="_blank" rel="noopener noreferrer">ç»¼è¿° | Brief.Bioinform. | ç»†èƒé—´é€šä¿¡æ¨æ–­çš„ç ”ç©¶è¿›å±•ä¸æŒ‘æˆ˜ï¼šå·¥å…·ã€èµ„æºåŠæœªæ¥æ–¹å‘çš„å…¨é¢ç»¼è¿°</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzU1MzMxMzcyMg==&amp;mid=2247790821&amp;idx=4&amp;sn=245af9481df2918b06674f76e5ef535f" target="_blank" rel="noopener noreferrer">Nature Neuroscienceï¼šææ˜/è‚–æ½‡/æœ±å³°/æ–¹è´»å„’åˆä½œæ­ç¤ºåŒç›¸æƒ…æ„Ÿéšœç¢é—ä¼ ç‰¹å¾å’Œç»†èƒæœºåˆ¶</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzkxODY4NDEwMA==&amp;mid=2247490106&amp;idx=1&amp;sn=7278c3bc770a69e7f2ec7ba04f975d7a" target="_blank" rel="noopener noreferrer">çº¿ç²’ä½“è‡ªå™¬</a></li>
</ul>
</div>
</details>

<details>
<summary><a name="æ›´å¤š-æ•°æ®å‰æ²¿"></a>ğŸ§¬ æ•°æ®å‰æ²¿ å…¶ä»–å†…å®¹ (34æ¡)</summary>
<div class="details-content">
<ul>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE289249" target="_blank" rel="noopener noreferrer">GSE289249 å¤šæ¢³æŠ‘åˆ¶å¤åˆç‰© 2 ä¸ DNA ç”²åŸºåŒ–ä¹‹é—´çš„ä¸²æ‰°ä»‹å¯¼ç¥ç»å†…åˆ†æ³Œå‰åˆ—è…ºç™Œè°±ç³»å¯å¡‘æ€§ [RRBS]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE287164" target="_blank" rel="noopener noreferrer">GSE287164 ISG20 ç¼ºå¤±å¯¹ EMT6 å°é¼ ä¹³è…ºç™Œç»†èƒåŸºå› è¡¨è¾¾çš„å½±å“ï¼ˆRNA-Seqï¼‰ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE286954" target="_blank" rel="noopener noreferrer">GSE286954 å‰åˆ—è…ºè…ºç™Œå’Œç¥ç»å†…åˆ†æ³Œå‰åˆ—è…ºç™Œæ¨¡å‹çš„è¡¨è§‚é—ä¼ å­¦åˆ†æï¼Œä»¥äº†è§£DNMT-EZH2çš„ç›¸äº’ä½œç”¨ã€‚[Cut&amp;Run]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE273769" target="_blank" rel="noopener noreferrer">GSE273769 PLK1 æŠ‘åˆ¶å‰‚ Onvansertib ä¸ FOLFIRI å’Œ Bevacizumab è”åˆç”¨äº KRAS çªå˜è½¬ç§»æ€§ç»“ç›´è‚ ç™Œçš„äºŒçº¿æ²»ç–—ï¼šä¸€é¡¹å•è‡‚ II æœŸè¯•éªŒã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE266604" target="_blank" rel="noopener noreferrer">GSE266604 å…ˆå…†å­ç—«èƒç›˜ç»„ç»‡çš„ç©ºé—´è½¬å½•ç»„åˆ†æ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE251960" target="_blank" rel="noopener noreferrer">GSE251960 Beckwith-Wiedemann ç»¼åˆå¾å’Œå¤§åä»£ç»¼åˆå¾æ¶‰åŠç”²åŸºåŒ–ç»„ã€è½¬å½•ç»„å’ŒæŸ“è‰²è´¨æ„å‹çš„æ”¹å˜ [RNA-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310509" target="_blank" rel="noopener noreferrer">GSE310509 SREBPä¿¡å·é€šè·¯è°ƒèŠ‚è‚ºéƒ¨é©»ç•™è®°å¿†Bç»†èƒä»£è°¢ä»¥ç»´æŒè¿‡æ•è®°å¿†</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311170" target="_blank" rel="noopener noreferrer">GSE311170 CDK12 å’Œ BAF æŠ‘åˆ¶å‰‚è”åˆä½¿ç”¨å¯ååŒæŠ‘åˆ¶ä¸‰é˜´æ€§ä¹³è…ºç™Œç»†èƒç³»çš„å­˜æ´»ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311157" target="_blank" rel="noopener noreferrer">GSE311157 åŒºåŸŸå‡è¡¡åŒ–å½’ä¸€åŒ–ä»¥æ”¹å–„è¡¨è§‚é—ä¼ ä¿¡å·çš„å¯¹é½</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE300112" target="_blank" rel="noopener noreferrer">GSE300112 å®«é¢ˆé˜´é“å¾®ç”Ÿç‰©ç»„ä¸äººç±»å®«é¢ˆå¤–ä¸Šçš®å’Œé»è†œä¸‹å±‚ä¸­ç©ºé—´å—é™çš„å®¿ä¸»è½¬å½•ç‰¹å¾ç›¸å…³</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE297099" target="_blank" rel="noopener noreferrer">GSE297099 æ¢å¤æœºæ¢°è¡¨å‹å¯é€†è½¬å¯Œå«ç»†èƒå¤–åŸºè´¨çš„å£°å¸¦ç™Œçš„æ¶æ€§ç‰¹å¾</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE289681" target="_blank" rel="noopener noreferrer">GSE289681 æ‹Ÿå—èŠ¥èŠ±å‘è‚²æ—©æœŸé˜¶æ®µèŠ±è¯±å¯¼ç³»ç»Ÿ (FIS) ä¸­ leunig_homolog (luh) å’Œ leunig (lug) çªå˜ä½“çš„è½¬å½•ç»„åˆ†æ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE278894" target="_blank" rel="noopener noreferrer">GSE278894 Sox9f/f å’Œ Sox9HKO å°é¼ åŸä»£è‚ç»†èƒè½¬å½•ç»„çš„ RNA-seq åˆ†æ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310962" target="_blank" rel="noopener noreferrer">GSE310962 EGFRçªå˜å‹å°ç»†èƒè‚ºç™Œå­˜åœ¨è‚¿ç˜¤å†…å¼‚è´¨æ€§ï¼Œå¯é€šè¿‡MEKæŠ‘åˆ¶å‰‚è”åˆç–—æ³•è¿›è¡Œé¶å‘æ²»ç–—ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE296748" target="_blank" rel="noopener noreferrer">GSE296748 Dp16 è‚è„è½¬å½•ç»„</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE296500" target="_blank" rel="noopener noreferrer">GSE296500 Crnicç ”ç©¶æ‰€äººç±»ä¸‰ä½“è®¡åˆ’ - 21ä¸‰ä½“æ¨¡å‹å›¾è°±ï¼šæ¥è‡ªæˆå¹´é‡ç”Ÿå‹å’ŒDp16å°é¼ è‚è„ç»„ç»‡ï¼ˆÂ±é«˜è„‚é¥®é£Ÿï¼‰çš„PolyA RNAæµ‹åº</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE296449" target="_blank" rel="noopener noreferrer">GSE296449 Crnicç ”ç©¶æ‰€äººç±»ä¸‰ä½“è®¡åˆ’ - 21ä¸‰ä½“æ¨¡å‹å›¾è°±ï¼šæ¥è‡ªäººç±»iPSCè¡ç”Ÿè‚ç»†èƒæ ·ç»†èƒçš„PolyA RNAæµ‹åº</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE296420" target="_blank" rel="noopener noreferrer">GSE296420 Crnicç ”ç©¶æ‰€äººç±»ä¸‰ä½“è®¡åˆ’ - 21ä¸‰ä½“æ¨¡å‹å›¾è°±ï¼šæ¥è‡ªæˆå¹´é‡ç”Ÿå‹å’ŒDp16å°é¼ è‚è„ç»„ç»‡çš„PolyA RNAæµ‹åº</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE295901" target="_blank" rel="noopener noreferrer">GSE295901 EBF1 å’Œ PAX5 å¯¹ T ç»†èƒè°±ç³»æ½œèƒ½å‘æŒ¥å‰‚é‡ä¾èµ–æ€§çš„è¡¨è§‚é—ä¼ æŠ‘åˆ¶ä½œç”¨ [ChIPmentation]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE295899" target="_blank" rel="noopener noreferrer">GSE295899 EBF1 å’Œ PAX5 å¯¹ T ç»†èƒè°±ç³»æ½œèƒ½å‘æŒ¥å‰‚é‡ä¾èµ–æ€§çš„è¡¨è§‚é—ä¼ æŠ‘åˆ¶ä½œç”¨ [scMultiome]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE195997" target="_blank" rel="noopener noreferrer">GSE195997 HIFæŠ‘åˆ¶å‰‚32-134Dè”åˆæŠ—PD-1ç–—æ³•å¯é˜»æ–­å°é¼ è‚ç»†èƒç™Œç”Ÿé•¿å¹¶æ ¹é™¤è‚¿ç˜¤</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311367" target="_blank" rel="noopener noreferrer">GSE311367 å¯¹è¡¨è¾¾é‡ç”Ÿå‹ RUNX1 å’ŒåµŒåˆè›‹ç™½ RUNX11-299-SPI11-102 çš„ 293T ç»†èƒè¿›è¡Œ DNA ç”²åŸºåŒ–åˆ†æ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE303684" target="_blank" rel="noopener noreferrer">GSE303684 YAP1åŠŸèƒ½éšœç¢ä¿ƒè¿›ä¸ä¹³è…ºç™Œæ˜“æ„Ÿæ€§ç›¸å…³çš„åˆ†å­ç‰¹æ€§</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE251961" target="_blank" rel="noopener noreferrer">GSE251961 Beckwith-Wiedemannç»¼åˆå¾å’Œå¤§åä»£ç»¼åˆå¾æ¶‰åŠç”²åŸºåŒ–ç»„ã€è½¬å½•ç»„å’ŒæŸ“è‰²è´¨æ„è±¡çš„æ”¹å˜</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE251959" target="_blank" rel="noopener noreferrer">GSE251959 Beckwith-Wiedemann ç»¼åˆå¾å’Œå¤§åä»£ç»¼åˆå¾æ¶‰åŠç”²åŸºåŒ–ç»„ã€è½¬å½•ç»„å’ŒæŸ“è‰²è´¨æ„å‹çš„æ”¹å˜ [WGBS]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311458" target="_blank" rel="noopener noreferrer">GSE311458 ä¸€é¡¹è¯„ä¼°è¥¿è¾¾ç±³å¾·è”åˆç»´å¥ˆæ‰˜å…‹ã€é˜¿æ‰èƒè‹·ã€é˜¿å…‹æ‹‰éœ‰ç´ ã€é˜¿ç³–èƒè‹·å’Œç²’ç»†èƒé›†è½åˆºæ¿€å› å­æ²»ç–—éš¾æ²»æ€§/å¤å‘æ€§æ€¥æ€§é«“ç³»ç™½è¡€ç—…çš„ I æœŸç ”ç©¶ï¼šä¸´åºŠå®‰å…¨æ€§ã€æœ‰æ•ˆæ€§å’Œç›¸å…³æ€§åˆ†æ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311175" target="_blank" rel="noopener noreferrer">GSE311175 å•ç»†èƒå¤šç»„å­¦åˆ†ææ­ç¤º CTCF æ˜¯è‚ºå½¢æ€å‘ç”Ÿå’Œç¥–ç»†èƒç»´æŒçš„å…³é”®è°ƒæ§å› å­ I</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311050" target="_blank" rel="noopener noreferrer">GSE311050 æŠ—ä½“å¤šæ ·æ€§äº§ç”Ÿçš„æŸ“è‰²è´¨æŠ˜å åŸç†</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE306856" target="_blank" rel="noopener noreferrer">GSE306856 Venetoclax é€šè¿‡è„‚è‚ªé…¸æ°§åŒ–å¢å¼ºå¤å‘æ€§æ€¥æ€§é«“ç³»ç™½è¡€ç—…ä¸­ Î³Î´T ç»†èƒçš„æŠ—ç™½è¡€ç—…æ´»æ€§ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE283418" target="_blank" rel="noopener noreferrer">GSE283418 æä»æ ¸ç¥ç»å…ƒçš„ç©ºé—´åˆ†å­è°±åˆ†æå®ç°äº†é’ˆå¯¹ç–¼ç—›ä¸é€‚çš„ç²¾å‡†è¯ç†å­¦æ²»ç–—</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE283060" target="_blank" rel="noopener noreferrer">GSE283060 äººæºåŒ–å•é…°ç”˜æ²¹é…°åŸºè½¬ç§»é…¶ 2 å°é¼ åœ¨å–‚é£Ÿé«˜è„‚é¥®é£Ÿåä¼šå˜å¾—è‚¥èƒ–å¹¶å‘å±•ä¸ºä»£è°¢åŠŸèƒ½éšœç¢ç›¸å…³çš„è„‚è‚ªè‚ç–¾ç—…</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE282984" target="_blank" rel="noopener noreferrer">GSE282984 åŸºäºç½‘ç»œè¯ç†å­¦å’Œè½¬å½•ç»„å­¦æ¢ç´¢èŠ¥é…¸çš„æŠ—æµæ„Ÿæœºåˆ¶</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE282864" target="_blank" rel="noopener noreferrer">GSE282864 é˜»å¡æ€§ç¡çœ å‘¼å¸æš‚åœæ‚£è€…è¡€æµ†å¤–æ³Œä½“microRNAçš„å·®å¼‚è¡¨è¾¾è°±</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE270116" target="_blank" rel="noopener noreferrer">GSE270116 æ·‹å·´æ¯’ç´ Î±æ˜¯æ€¥æ€§é«“ç³»ç™½è¡€ç—…çš„å†…æºæ€§æŠ‘åˆ¶å› å­</a></li>
</ul>
</div>
</details>

<hr />
<p><em>ğŸ“… æŠ¥å‘Šç”Ÿæˆæ—¶é—´ï¼š2025-11-26 21:34</em><br />
<em>ğŸ¤– ç”± GitHub Actions è‡ªåŠ¨ç”Ÿæˆ</em></p>
    </div>
</body>
</html>